OBJECTIVES: To determine the frequency and characteristics of clinical signs, symptoms, laboratory findings, and medication use in children with pediatric systemic lupus erythematosus (pSLE) at presentation and during the course of the disease, and to examine correlations among disease manifestations, disease activity, and damage over time. STUDY DESIGN: The study involved an analysis of medical records and the SLE database of an inception cohort of 256 patients with pSLE (female:male ratio, 4.7:1). RESULTS: The most common clinical manifestations were arthritis (67%), malar rash (66%), nephritis (55%), and central nervous system (CNS) disease (27%). At diagnosis, patients with both renal and CNS disease had the highest SLE Disease Activity Index (SLEDAI) scores (P < .0001), but these scores were similar to those of the total group at 1 year (P = .11). Patients who developed renal and CNS disease more than 1 year after diagnosis had higher SLEDAI scores at disease onset. Some 34% of patients had Systemic Lupus International Collaborative Clinics Damage Index (SLICC-DI) scores >1 at a mean follow-up of 3.5 years. A greater proportion of patients with renal and CNS disease had SLICC-DI scores of >1, and these patients had higher mean scores compared with patients without major organ involvement (70% vs 11% [P < .0001] and 1.4 vs 0.1 [P < .0001], respectively). CONCLUSIONS: Most of the patients in our cohort exhibited major organ involvement. These patients had the highest SLEDAI scores at diagnosis, which normalized at 1 year but preceded development of renal and CNS disease. The average SLICC-DI score was lower than that previously reported in patients with pSLE.
OBJECTIVES: To determine the frequency and characteristics of clinical signs, symptoms, laboratory findings, and medication use in children with pediatric systemic lupus erythematosus (pSLE) at presentation and during the course of the disease, and to examine correlations among disease manifestations, disease activity, and damage over time. STUDY DESIGN: The study involved an analysis of medical records and the SLE database of an inception cohort of 256 patients with pSLE (female:male ratio, 4.7:1). RESULTS: The most common clinical manifestations were arthritis (67%), malar rash (66%), nephritis (55%), and central nervous system (CNS) disease (27%). At diagnosis, patients with both renal and CNS disease had the highest SLE Disease Activity Index (SLEDAI) scores (P < .0001), but these scores were similar to those of the total group at 1 year (P = .11). Patients who developed renal and CNS disease more than 1 year after diagnosis had higher SLEDAI scores at disease onset. Some 34% of patients had Systemic Lupus International Collaborative Clinics Damage Index (SLICC-DI) scores >1 at a mean follow-up of 3.5 years. A greater proportion of patients with renal and CNS disease had SLICC-DI scores of >1, and these patients had higher mean scores compared with patients without major organ involvement (70% vs 11% [P < .0001] and 1.4 vs 0.1 [P < .0001], respectively). CONCLUSIONS: Most of the patients in our cohort exhibited major organ involvement. These patients had the highest SLEDAI scores at diagnosis, which normalized at 1 year but preceded development of renal and CNS disease. The average SLICC-DI score was lower than that previously reported in patients with pSLE.
Authors: Hermine I Brunner; Marisa S Klein-Gitelman; Gloria C Higgins; Sivia K Lapidus; Deborah M Levy; Anne Eberhard; Nora Singer; Judyann C Olson; Karen Onel; Marilynn Punaro; Laura Schanberg; Emily von Scheven; Jun Ying; Edward H Giannini Journal: Arthritis Care Res (Hoboken) Date: 2010-06 Impact factor: 4.794
Authors: Hermine I Brunner; Gloria C Higgins; Marisa S Klein-Gitelman; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Edward H Giannini Journal: Arthritis Care Res (Hoboken) Date: 2010-07 Impact factor: 4.794
Authors: Kit San Yeung; Tsz Leung Lee; Mo Yin Mok; Christopher Chun Yu Mak; Wanling Yang; Patrick Chun Yin Chong; Pamela Pui Wah Lee; Marco Hok Kung Ho; Sanaa Choufani; Chak Sing Lau; Yu Lung Lau; Rosanna Weksberg; Brian Hon Yin Chung Journal: Epigenetics Date: 2019-03-16 Impact factor: 4.528
Authors: Asma Al Rasbi; Eiman Abdalla; Rabab Sultan; Nasreen Abdullah; Juma Al Kaabi; Ibrahim Al-Zakwani; Reem Abdwani Journal: Rheumatol Int Date: 2018-05-02 Impact factor: 2.631
Authors: Linda T Hiraki; Candace H Feldman; Jun Liu; Graciela S Alarcón; Michael A Fischer; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2012-08